Ingevity Corporation

Day range

$70.04 – $72.13

Open

$70.20

Prev close

$69.64

Volume

367.73K

Market cap

$2.39B

Shares out

34.38M

P/E

44.33

P/S

2.06

P/B

51.05

P/FCF

15.46

ROE

115.1%

ROA

3.5%

Debt/Equity

25.59

Div yield

0.00%

As of Oct 23, 2026

• Preliminary resultsJul 29, 2026

  On July 29, 2026, Ingevity Corporation ("Ingevity") announced its preliminary financial results for the three and six months ended June 30, 2026 which are attached as Exhibit 99.1 to this Current Report on Form 8-K.

• Executive officer appointmentJun 24, 2026

  On June 22, 2026, Ryan Cotterman, age 44, was appointed as Vice President, Chief Accounting Officer and principal accounting officer of Ingevity Corporation (the "Company"). Mr. Cotterman most recently served as Senior Director, Corporate Controller of Ralliant Corporation (NYSE: RAL)... Earlier in his career, Mr. Cotterman spent 14 years with Ernst & Young LLP, rising to Assurance Services Senior Manager (2004–2017).

• Preliminary resultsMay 6, 2026

  On May 6, 2026, Ingevity Corporation announced its preliminary financial results for the three months ended March 31, 2026 which are attached as Exhibit 99.1 to this Current Report on Form 8-K.

• Annual meeting resultsMay 4, 2026

  At the Annual Meeting, the Company's stockholders voted on the four proposals identified below... The final voting results for each proposal voted upon at the Annual Meeting are described below. 1. Election of the nine (9) director nominees listed below, each for a one-year term... 2. Approval, on a non-binding, advisory basis, of the compensation of the Company's named executive officers. 3. Ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for fiscal 2026. 4. Approval of amendment to increase authorized shares under the Ingevity Corporation 2025 Omnibus Incentive Plan.

• Credit facilityMar 30, 2026

  entered into that certain Second Amendment and Restatement Agreement (the "Amendment"), which amends and restates the Amended and Restated Credit Agreement, dated as of June 23, 2022... The Amendment amends and restates the Existing Credit Agreement to, among other things, (a) extend the maturity date of the Company's revolving credit facility to the date that is five years after the Closing Date, (b) decrease the aggregate amount of the commitments thereunder from $1 billion to $750 million and (c) effect certain other amendments.

• AVNTAvient Corporation+0.61%
• IOSPInnospec Inc.+0.55%

Days to cover

4.8

Short interest

1.46M

Avg volume

305.63K

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Is NGVT Positioned for Further Adjusted EBITDA Improvement?
  positiveZacks Investment Research· Oct 15, 2026
• Here's Why You Should Hold Onto Ingevity Stock for Now
  neutralZacks Investment Research· Oct 7, 2026
• NGVT Stock Rallies 31% in a Year: What's Driving the Upside?
  positiveZacks Investment Research· Sep 30, 2026
• Global Activated Carbon Market Outlook 2026-2033: Water Treatment, Air Purification and Emissions Control Demand Surges
  positiveGlobeNewswire Inc.· Sep 24, 2026
• Ingevity Shares Rise 19.2% YTD: Can the Stock Sustain the Rally?
  positiveZacks Investment Research· Sep 8, 2026